Amoxicillin

證據等級: L5

預測適應症: 8 個

Amoxicillin: From Bacterial Infections to Monoclonal Gammopathy

One-Sentence Summary

Amoxicillin is a broad-spectrum beta-lactam antibiotic with well-established activity against a wide range of bacterial pathogens, including Helicobacter pylori as part of standard eradication triple therapy. The TxGNN model predicts it may be effective for Monoclonal Gammopathy — most specifically the immunoproliferative small intestinal disease (IPSID / α-heavy chain disease) subtype — with 1 clinical trial and 11 publications identified in support. Among the 8 predicted indications in this multi-indication pack, monoclonal gammopathy carries the strongest evidence (L3) and the only actionable recommendation (“Proceed with Guardrails”), grounded in a recognised antibiotic-responsive disease mechanism codified in the WHO tumour classification.

Quick Overview

Item	Content
Original Indication	Broad-spectrum bacterial infections (penicillin-class antibiotic)
Predicted New Indication	Monoclonal Gammopathy (IPSID subtype)
TxGNN Prediction Score	99.22%
Evidence Level	L3
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from this evidence pack (Data Gap DG002). Based on established pharmacology, Amoxicillin is an aminopenicillin that inhibits bacterial cell wall synthesis by covalently binding penicillin-binding proteins (PBPs), leading to bacteriolysis. Its reliable activity against Helicobacter pylori makes it a cornerstone of H. pylori eradication triple therapy (e.g., amoxicillin + clarithromycin + proton pump inhibitor), and this property forms the primary mechanistic bridge to its potential utility in monoclonal gammopathy.

Immunoproliferative Small Intestinal Disease (IPSID) — also known as α-heavy chain disease or Mediterranean lymphoma — is an extranodal marginal zone B-cell lymphoma (MALT-type) of the small intestine, driven by chronic mucosal infection, particularly Campylobacter jejuni and potentially H. pylori. Sustained bacterial antigenic stimulation promotes clonal proliferation of IgA-secreting B cells that produce truncated, non-functional α-heavy chains. Critically, in Stage A (early) disease, prolonged antibiotic regimens — including ampicillin, tetracycline, and amoxicillin-containing H. pylori eradication protocols — can induce durable complete remission without cytotoxic chemotherapy. This is not experimental: the strategy is explicitly recognised in the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues as a standard first-line approach for Stage A IPSID.

It is essential to emphasise that this rationale applies exclusively to the IPSID subtype of monoclonal gammopathy. Other subtypes — MGUS, multiple myeloma, Waldenström macroglobulinaemia, and light chain amyloidosis — have entirely distinct pathophysiology unrelated to bacterial infection, and there is no mechanistic or clinical basis for antibiotic therapy in those conditions. The high TxGNN score (99.22%) most likely reflects the model’s knowledge graph linking the “antibiotic” drug class node to the “monoclonal gammopathy” disease node via the IPSID subtype relationship, rather than a generalised signal across all subtypes.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00062231	N/A	Terminated	351	Oral empirical antibiotic therapy for febrile neutropenia in low-risk cancer patients: amoxicillin + ciprofloxacin vs. moxifloxacin monotherapy. Not a direct treatment trial for monoclonal gammopathy; supports the safety profile of amoxicillin in haematological malignancy patients and establishes tolerability in an immunocompromised oncology context.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9030995	1996	Case Series + Narrative Review	Internal Medicine (Tokyo)	Mediterranean lymphoma (IPSID) treated with antibiotics; complete remission achieved with antibiotic monotherapy, supporting the antibiotic-first strategy in early-stage IPSID — directly relevant to repurposing rationale
8988128	1997	Case Report	Lancet	Regression of IPSID following H. pylori eradication; demonstrates that eliminating the bacterial driver reverses B-cell clonal proliferation and tumour regression — key mechanistic evidence
20300878	2010	Case Report	J Gastrointestinal Cancer	Regression of IPSID after H. pylori eradication in a 20-year-old male; corroborates the infection-driven pathogenesis and antibiotic responsiveness
16253033	2005	Case Report	Arch Pathol Lab Med	Nonsecretory variant of IPSID with pathologic and molecular characterisation; broadens disease spectrum understanding, relevant for diagnosis and treatment staging
35619805	2022	Case Report	Front Public Health	Disseminated nocardiosis in a patient with macroglobulinaemia; isolated strain susceptible to amoxicillin/clavulanic acid — confirms activity and tolerability in plasma cell dyscrasia patients
22092390	2012	Retrospective Comparative Study	J Oral Pathol Med	Bisphosphonate-related osteonecrosis of the jaw (BRONJ) in multiple myeloma vs. breast cancer; amoxicillin used as adjunct antibiotic in the standardised management protocol — safety reference in myeloma patients
20015614	2010	Retrospective Case Series	Int J Oral Maxillofac Surg	Surgical management of bisphosphonate-induced ONJ not responding to conservative treatment; amoxicillin incorporated in peri-operative antibiotic coverage — additional safety evidence in haematological malignancy setting
18639371	2009	Retrospective Cohort	Br J Oral Maxillofac Surg	Bisphosphonate-associated ONJ following therapy discontinuation; amoxicillin part of supportive infection management in myeloma/metastatic cancer patients
21908119	2011	Case Report	Médecine et Maladies Infectieuses	Pneumonia caused by Rothia dentocariosa in a haematology patient; indirect evidence of amoxicillin use in immunocompromised haematological malignancy patients
20513124	2010	Retrospective Diagnostic Study	Am J Hematol	High false-positive rate of Aspergillus galactomannan test in multiple myeloma; antibiotic co-administration (including beta-lactams) noted as a confounding factor — contextualises antibiotic use in myeloma management

Philippines Market Information

Amoxicillin currently has no registered products in the FDA Philippines database according to this evidence pack.

Important caveat: Amoxicillin is one of the most widely distributed generic antibiotics globally and is included on the WHO Essential Medicines List. The absence of registration records here likely reflects a data gap in the current dataset rather than actual market absence in the Philippines. Independent verification with the FDA Philippines online registry (https://www.fda.gov.ph) is strongly recommended before drawing conclusions about market availability.

Safety Considerations

Safety data was not available in this evidence pack (DG001: Philippine FDA labelling data gap). Please refer to the package insert for complete warnings, contraindications, and precautions.

Based on established class-level knowledge for aminopenicillins, the following are known considerations for clinical reference:

Hypersensitivity: IgE-mediated anaphylaxis and delayed hypersensitivity reactions are the most serious class risks; cross-reactivity with other beta-lactams applies
Superinfection: Prolonged courses may lead to Clostridioides difficile-associated diarrhoea (CDAD), which is particularly relevant in the IPSID indication where long-term antibiotic treatment is required
Maculopapular rash: Significantly elevated incidence in patients with infectious mononucleosis, lymphocytic leukaemia, or concurrent allopurinol use — relevant in haematological malignancy patients

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The IPSID (Stage A) subtype of monoclonal gammopathy has a well-characterised infection-driven pathogenesis in which amoxicillin-based antibiotic eradication of H. pylori / C. jejuni is a recognised, WHO-endorsed first-line treatment capable of inducing complete remission without chemotherapy. Observational case series and mechanistic literature (L3) support biological plausibility and provide clinical precedent, though no randomised controlled trials evaluating amoxicillin specifically for IPSID have been conducted.

To proceed, the following is needed:

Subtype confirmation is mandatory: Restrict any clinical application strictly to IPSID (Stage A); MGUS, multiple myeloma, and Waldenström macroglobulinaemia subtypes do not benefit from antibiotics and should be excluded from this repurposing pathway
Retrieve complete MOA data from DrugBank (DG002 remediation) to formalise mechanism documentation
Obtain Philippine FDA package insert (DG001 remediation) for complete local warnings, contraindications, and dosage guidance
Pathogen prevalence assessment: Evaluate regional prevalence of H. pylori and C. jejuni in the Philippine target population, as treatment success rates depend directly on pathogen eradication rates
Prospective registry or pragmatic trial: Consider a registry study enrolling Stage A IPSID patients in the Philippines to document antibiotic response rates with locally available amoxicillin-based regimens
Endoscopy and staging protocol: Confirm that local diagnostic capacity (upper GI endoscopy, immunohistochemistry, α-heavy chain immunofixation) is available to accurately stage IPSID before initiating antibiotic-only therapy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.